Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd., a foreign private issuer, for the month of September 2016. The report discloses an immediate submission to the Israeli Securities Authority and the Tel Aviv Stock Exchange dated September 25, 2016.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event regarding intellectual property and contains no financial statements.
Material Changes
The material change disclosed is the Company's submission of a request for a patent regarding the extraction of mesenchymal stem cells and the separation of these stem cells from adult adipose cells.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the specific patent filing event.
Key Facts for Investor Verification
- The Company filed a patent request for mesenchymal stem cell extraction and separation technology on September 25, 2016.
- The report is a translation of an immediate report submitted to Israeli regulatory bodies.
- No financial performance data is included in this specific filing.